Audit: QRS - Laser Resurfacing for Skin Rejuvenation
Audit conducted on 11/09/2026 03:55 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells against Therapeutic Protocol (ER 369–377), time cells against Practical Considerations (ER 431) and Discontinuation & Cycling (ER 409, 411), gates against Key Interactions & Contraindications (ER 310–343), tiers against Expected Benefits / Potential Risks & Side Effects, table against the Monitoring biomarker table (ER 459–468). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | HSV-1 IgG row carries the ER’s “No established target” wording (QRS 779 vs ER 468); speculative items stay in the Speculative tier rather than being promoted. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute contraindications stay in the Contraindications gate (gold therapy, pregnancy, phototype V–VI fully ablative); caution-level entries stay in Key Interactions, with “absolute contraindication at high doses” retained for immunosuppressants (QRS 605–606). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from Benefit-Modifying Factors (ER 208–218) or Risk-Modifying Factors (ER 298–306) appears in any gate or tier; every gate item traces to Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, expert names, NCT identifiers or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present; ER attributions (Duplechain, Pozner, Geronemus, Fraxel) were correctly dropped rather than restated. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, data-first register matching the ER; the lede mirrors the ER Conclusion phrasing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Clinical terms in the body, plain terms in the lede; trade-offs presented without hedging or alarm. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives or instructions to act; items are descriptive noun phrases. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “recommended” or dosing directives addressed to a reader outside the template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Gates are stated as conditions and agents, not as instructions. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the populated spans. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained only where they are the ER’s own endpoint names; the lede is jargon-free. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a short phrase; no sentences carry rationale or study detail. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Biomarker optimisation panel, pre-session metabolic markers and the skin-cancer-incidence benefit are framed for a proactive audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Multi-session schedules, 7–14 days of open wound care, four-week smoking cessation and strict photoprotection are presented without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No reassurance or effort-minimising framing; downtime and pain are stated plainly. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede foregrounds the skin-cancer-incidence finding, which the ER identifies as the outcome that matters most to a longevity-focused reader (ER 166, 497). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Anti-aging” does not occur; the speculative benefit uses “tissue-level longevity mechanism” (QRS 560–561). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Body uses “post-inflammatory hyperpigmentation”, “erythema, edema and crusting”, “ectropion”; the lede’s plainer terms (“brown-spot fading”, “herpes flare-ups”) are the ER Conclusion’s own wording (ER 497, 499). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings are byte-identical to [qrs_template] (QRS 446, 491, 540, 570, 592, 635, 664, 668–670, 803). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# blocks are expanded to marker_1–8 and qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff against [qrs_template] shows changes confined to the metadata block and the variable regions; CSS, markup, comments and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty; every benefit tier, risk tier, gate and monitoring block has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels carry the ER’s bold approach names (ER 369, 371, 373); monitoring row labels reproduce the ER biomarker names verbatim including the parenthetical abbreviations (HbA1c, hs-CRP, HSV-1 IgG). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; the time-to-effect sub-labels (“Wrinkle and texture gains”, “Final result”, “Pigment gains”) use the ER’s own wording from the Time to effect bullet (ER 431). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Codepoint scan returns no emoji; the ER’s 🟩/🟥/🟨 tier markers and the melasma ⚠️ marker were all dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the template’s single-sheet structure — gate items are one line each, tier items are comma-chained single lines, and no section was duplicated or extended beyond the template’s print layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS 2–14: the metadata comment opens on line 2, directly after <!doctype html>, before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on QRS 3, closing --- on QRS 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Entirely inside the HTML comment; no metadata value is echoed on the sheet except the header date and model, which are their own variables. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | QRS 4: er_filename: laser_resurfacing_skin_2026-0911-0217_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | QRS 5: qrs_prompt_version: 26.7.02, matching the version badge of [qrs_prompt]. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | QRS 6: qrs_creation_date: 2026-0911-0348. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | QRS 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | QRS 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no context-window or tier qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | QRS 9 matches the actual filename laser_resurfacing_skin_2026-0911-0217_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS 22: “Laser Resurfacing for Skin Rejuvenation - Quick Reference Sheet”; ER canonical_topic is identical and contains no characters needing encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS 417: “Laser Resurfacing for Skin Rejuvenation”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS 421: 09/11/2026, correctly derived from qrs_creation_date: 2026-0911-0348. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” list (ER 30) was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | QRS 434–438 condenses ER 497–499: mechanism, the three strongest benefits, the weaker pigment benefit, durability, the skin-cancer finding and the cost profile. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words by token count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct ER Conclusion sentence (ER 497 for mechanism, benefits, durability and the skin-cancer result; ER 499 for the cost profile). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “rhytides” → “wrinkled skin”, “atrophic acne scars” → “depressed acne scars”, “actinic keratoses” → “rough sun-damaged patches”, “solar lentigines” → “brown-spot”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Only qualitative magnitudes (“fewer new skin cancers”, “a year or two”); no percentages, risk ratios or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items come from “Populations who should avoid Laser Resurfacing” (ER 330–343) plus the gold-therapy absolute contraindication (ER 318). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Twelve ER avoid-list bullets map one-to-one to the twelve <li> entries (QRS 573–587); none dropped, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is its own <li> inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationale clauses are all stripped: “because injury seeds new lesions” (ER 336), “which destroys the adnexal cells needed for repair” (ER 338), “because of anaesthetic and prophylactic drug exposure” (ER 339), “where permanent pigment loss risk is prohibitive” (ER 340). No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “(glycated haemoglobin above 8%)”, “Fitzpatrick phototypes V–VI”, “within four weeks before and after treatment”, “within four weeks”, “at any point in life”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names twelve such populations, and the section is populated accordingly. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from the bulleted interaction list at ER 310–328. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets appear; parenteral gold therapy (ER 318, “Absolute contraindication”) is correctly excluded here and placed in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is its own <li> inside the caution_items span (QRS 595–625). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic and consequence sentences are all stripped (“Increased bruising, oozing and prolonged crusting”, “Hypericin is photosensitising…”, the 2017 systematic-review citation at ER 310, the pooled-facelift citation at ER 328). No dash-trailing clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list is carried through intact (warfarin/apixaban/clopidogrel/low-dose aspirin; doxycycline/hydrochlorothiazide/amiodarone/voriconazole; prednisone/tacrolimus/mycophenolate; the nine-item clotting list; the topical-actives list; vitamin C/zinc/collagen peptides/arnica/bromelain; the seven stacked interventions), together with the 7–10 day, 5–7 day and two-week windows and the “absolute contraindication at high doses” severity qualifier. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets contain no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interactions, and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol 369–377. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The ER’s three named approaches — fully ablative, ablative fractional, non-ablative fractional — are the section’s load-bearing decision, since ER 375 states no approach is the default. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct approaches, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Each value carries the ER’s session count and spacing; each sub carries device, downtime and, for the fractional cells, the ER’s representative settings (ER 377). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Wrinkle/texture at three months, final result at six months and pigment at one month are exactly the three milestones in ER 431. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Wrinkle and texture gains first (the ER’s High-tier, best-evidenced benefit), then the overall six-month endpoint, then pigment gains, tied to a Medium-tier benefit the ER calls the least durable. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect milestones, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Subs add the ER’s durability facts: 24-month stability of fractional CO₂ (ER 409), the six-month remodelling endpoint (ER 457), and pigment reversion within three months without photoprotection (ER 411). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data (ER 431), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten items trace to the ER’s tiered benefit headings (ER 144–204). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at the correct tiers (QRS 542–563). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER’s bare endpoint name; all Magnitude lines, mechanism paragraphs and the melasma “Conflicted” marker are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefit item; the ER’s glosses (e.g. “basal and squamous cell skin cancers”, ER 166) are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items (3 High, 4 Medium, 1 Low, 2 Speculative), so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven items trace to the ER’s tiered risk headings (ER 226–294). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at the correct tiers (QRS 637–658). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER’s bare complication name; all frequencies (38.4%, 10.6%, 5.2%, 5 of 1,093) and mechanism text are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain; the ER’s glosses (“raised and thickened”, “sunken”, “small keratin cysts”) are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items (6 High, 2 Medium, 2 Low, 1 Speculative), so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both derive from ER Monitoring Protocol & Defining Success (ER 457–468). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarker rows are present in ER order — HbA1c, 25-hydroxyvitamin D, hs-CRP, ferritin, zinc, albumin, haemoglobin, HSV-1 IgG — with targets and “Why” text matching the ER table. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS 792–797 reproduces the ER cadence: day 3–7 wound check, two-week closure, 4–6 week pigment assessment, three- and six-month photography, metabolic recheck before subsequent sessions, actinic keratosis counts every 6–12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s qualitative-marker list (ER 472–477). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Six of six ER qualitative markers present, in ER order and wording (QRS 806–835). |
Issues 11/09/2026 03:55
Pass rate 100.00%. No issues found.